Mosapride- Korea United Pharm

Drug Profile

Mosapride- Korea United Pharm

Alternative Names: UI05MSP015CT

Latest Information Update: 16 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Korea United Pharm Inc
  • Class Antiulcers; Benzamides; Gastrokinetics; Morpholines; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dyspepsia

Most Recent Events

  • 16 Jun 2017 Chemical structure information added
  • 26 May 2017 Korea United Pharm has patents pending for mosapride in USA
  • 06 May 2017 Efficacy and adverse events data from a phase III trial in Dyspepsia presented at the Digestive Disease Week 2017 (DDW-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top